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Abstract
Background:  Malignant gliomas are frequent primary brain tumors associated with poor
prognosis and very limited response to conventional chemo- and radio-therapies. Besides sharing
common growth features with other types of solid tumors, gliomas are highly invasive into adjacent
brain tissue, which renders them particularly aggressive and their surgical resection inefficient.
Therefore, insights into glioma formation are of fundamental interest in order to provide novel
molecular targets for diagnostic purposes and potential anti-cancer drugs. Human Tripartite motif
protein 3 (TRIM3) encodes a structural homolog of Drosophila brain tumor (brat) implicated in
progenitor cell proliferation control and cancer stem cell suppression. TRIM3 is located within the
loss of allelic heterozygosity (LOH) hotspot of chromosome segment 11p15.5, indicating a
potential role in tumor suppression. ...
Methods: Here we analyze 70 primary human gliomas of all types and grades and report somatic
deletion mapping as well as single nucleotide polymorphism analysis together with quantitative real-
time PCR of chromosome segment 11p15.5.
Results: Our analysis identifies LOH in 17 cases (24%) of primary human glioma which defines a
common 130 kb-wide interval within the TRIM3 locus as a minimal area of loss. We further detect
altered genomic dosage of TRIM3 in two glioma cases with LOH at 11p15.5, indicating homozygous
deletions of TRIM3.
Conclusion:  Loss of heterozygosity of chromosome segment 11p15.5 in malignant gliomas
suggests TRIM3 as a candidate brain tumor suppressor gene.
Background
Malignant gliomas are brain tumors that represent devas-
tating and difficult-to-treat cancers with a mean patient
survival of 10 months. Although surgical interventions
allow resection and improve local tumor control, the fur-
ther course of the disease remains dominated by re-
appearance of unscheduled cell proliferation and insidi-
ous infiltration of normal brain tissue. Especially glioblas-
tomas appear notoriously resistant to therapy, which has
been attributed to DNA-repair proficiency and deregu-
lated molecular pathways [1,2]. More recently combined
chemoradiotherapy of concomitant and adjuvant temo-
zolomide and radiotherapy has been introduced which
can lead to significant prolongation of survival, in partic-
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ular in patients with an epigenetically silenced DNA repair
gene [3]. However, the outcome remains poor. This ther-
apeutic resistance has recently been attributed to tumor
stem-like cells due to their unrestrained self-renewal
capacity and the ability to maintain tumorigenic potential
at the single cell level, thereby evading both resection and
radiotherapy [4-7]. There is growing evidence that some
brain cancers arise either from normal stem cells or from
progenitor cells in which self-renewal pathways have
become aberrantly activated [7-10].
Drosophila Brain tumor (brat) has been identified as a reg-
ulator of progenitor cell proliferation control and cancer
stem cell suppression [11-18]. Brat is expressed through-
out Drosophila brain development and exerts an essential
gate-keeper function in the binary switch between self-
renewal and differentiation of neural progenitor cells.
Neural progenitor cells mutated for Brat are unable to dif-
ferentiate but rather continue to proliferate, resulting in
brat mutant cells that display characteristic features of can-
cer-like stem cells. The resulting brain tumor tissue is char-
acterized by pleiomorphic cells, continued proliferation
and chromosome instability, as evidenced by a variety of
karyotypic abnormalities [19].
Homologues of brat have been recorded in various spe-
cies, with three human homologues, namely Tripartite
Motif Protein 2 (TRIM2), TRIM3, and TRIM32, located on
chromosome 4q31.3, 11p15.5, and 9q33.1, respectively
[20-23]. 11p15 represents the telomeric end of chromo-
some 11 which shows loss of allelic heterozygosity (LOH)
in various types of tumors, indicating the presence of one
or more tumor suppressor genes [24-27]. Homologues of
TRIM3 are primarily expressed in brain and may function
at the interface of proliferation and differentiation during
the maturation of brain tissue [28-30]. Here we report
refined deletion mapping of chromosome 11p15.5 in
malignant gliomas.
Methods
Biopsies and DNA extraction
Tumor samples used in this study were obtained from 70
patients who underwent glioma resection at the Univer-
sity Hospital of Basel between 1996 and 2005. The collec-
tion of tumor samples has been approved by the Ethics
Committee of Basel-Land and Basel-Stadt (EKBB).
Informed consent has been obtained together with the
patient's permission to conduct open brain surgery, con-
senting to the use of biopsies for anonymous scientific
research. This procedure follows the present recommen-
dations of the Swiss Academy of Medical Sciences as pro-
posed in 2008 and is in compliance with the Helsinki
Declaration. Tumors were classified according to the
revised WHO classification of tumors of the nervous sys-
tem [31], comprising 10 oligodendrogliomas grade II, 13
astrocytomas grades I to III, and 47 glioblastoma multi-
forme [see Additional file 1]. DNA was extracted from
fresh frozen primary gliomas and peripheral blood mono-
nuclear cells (PBMCs) derived from the same patients, as
previously described [32,33]. Only material containing
less than 30% residual amounts of non-neoplastic cells
was considered for further analysis.
STS- and SNP-based LOH analysis
Sequence tagged site (STS)-based LOH was performed
essentially as described [32]. Briefly, DNA from 70 glioma
specimens and PBMCs of the same patients was analysed
for loss of heterozygosity by amplification of microsatel-
lite sequences [32]. Primers for these sequences were
obtained from Microsynth (Balgach, Switzerland). Fluo-
rescence based LOH mapping was employed with DNA
from all gliomas. D11S4905 (located in TRIM3 intron 2)
and D11S1250 primers were FAM-labeled, D1S1318 and
D11S1758 primers were HEX-labeled, and D11S1331 and
D11S1997 primers were TET-labeled. PCR product size
fractionation and quantification were performed on ABI
Prism 310 Genetic Analyzer (PE Applied Biosystems, Fos-
ter City, CA, USA). The ratio of peak heights of both alleles
was calculated for each tumor and PBMC DNA sample.
For informative cases, allelic loss was scored if the ratio
between tumor and PBMC DNA was more than 1.5 (1/0)
or less than 0.66 (0/2). Single nucleotide polymorphism
(SNP)-based LOH was performed with the following
markers: rs11605881 (TRIM3  promoter), rs11607224
(exon1), rs1060067 (exon4) rs16913748 (exon6),
rs11605141 (intron6), rs13343175 (intron7), rs3830325
(intron9), rs2306897 (exon10) and rs2723636 (exon13).
SNPs were visualized on an ABI Prism 310 Genetic Ana-
lyzer (PE Applied Biosystems, Foster City, CA, USA).
Quantitative real-time PCR
Classification of the genetic status of TRIM3  was per-
formed by quantitative real-time-PCR using the TaqMan
ABI Prism® 7700 Sequence Detection System (PE Applied
Biosystems, Foster City, CA, USA) as previously described
[34]. Gene-specific primers for the reference-control
GAPDH, which is located on chromosome 12p13.3, as
well as primers for Intron1, Exon 3, Intron 6, Intron 11
and cDNA of TRIM3 were used as follows:
For GAPDH:
5'-AATGGGACTGAGGCTCCAC (sense),
5'-TTATGGGAAAGCCAGTCCCC (antisense).
For TRIM3 Intron 1:
5'-CCCCAAGGGTGCGTTTGTATT (sense),BMC Cancer 2009, 9:71 http://www.biomedcentral.com/1471-2407/9/71
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5'-TGCTCTCACGGACATGGACA (antisense).
For TRIM3 Exon 3:
5'-GCAGTTCCTGGTATGCAGCAT (sense),
5'-TGCAGGCAAGGAAGAACCTT (antisense).
For TRIM3 Intron 6:
5'-GGGCCAAACAGAAGGTGTGT (sense),
5'-GGCATGTCAGGAGGCAGAAT (antisense).
For TRIM3 Intron 11:
5'-AGGCAGTAGGGCACATGGAT (sense),
5'-GAGAACCCCCACCCAGATCT (antisense).
For TRIM3 cDNA Exons 7/8:
5'-GGCGGCAAACGAAAGGA (sense),
5'-CCTTCCACGACTGCCAACA (antisense).
Gene-specific double-dye FAM-TAMRA labelled oligo-
meric probes were:
For GAPDH: FAM-ATCCAAGACTGGCTCCTCCCTGCTG-
TAMRA.
For  TRIM3  Intron 1: FAM-CCCACAGCCGCTCCGAC-
CCA-TAMRA.
For  TRIM3  Exon 3: FAM-TGCCTGGATCGGTACCAGT-
GCCC-TAMRA.
For TRIM3 Intron 6: FAM-CACCAGCTCCCCATTCCCCA-
TAMRA.
For  TRIM3  Intron 11: FAM-CAGCTACAGCCCAAATCT-
GCTTCATAGGCTT-TAMRA.
For  TRIM3  cDNA: FAM-AACCCAATTGAGGAT-
GAGCTCGTCTTCC-TAMRA.
PCR conditions, primers and probe design were assessed
by the Primer Express® program (PE Applied Biosystems,
Foster City, CA, USA). Final primer concentration was 200
nM and fluorescent oligomeric probe concentration was
50 nM. Fifty ng genomic DNA derived from primary
tumor tissue was taken as template. Genomic DNA
amounts between normal and neoplastic tissues were
standardized by subtracting the respective threshold
cycles (Cts) obtained for the GADPH  gene. In this
approach the variable Ct is defined as the fractional cycle
number crossing a fixed threshold of fluorescence that has
been generated by cleavage of the probe due to polymer-
ase driven exonucleolytic activity. Differences in the Ct
values between two genes were referred to the ΔCt value.
After normalization of the tumor Ct values with the PBMC
Ct values, the ΔCtvalues and the relative copy number of
Introns1, 6 and 11, as well as Exon 3 of TRIM3 were cal-
culated as follows: ΔCt (X) = Ct (reference) - Ct (X). Thus,
ΔCt values of 0 ± 0.3 [-0.3;+0.3] indicated retention of
both alleles (diploidy = 2n) and ΔCt values of -1 ± 0.3 [-
0.7;-1.3] indicated loss of one allele (haploidy = n). Due
to the frequent contamination of tumor biopsy DNA by
that of invaded normal tissue, ΔCt values of < -1.30 were
accounted as indicative for homozygous deletions. All
analyses of tumor samples were performed in triplicate in
parallel with PBMC DNA, and data indicating
homozygous deletions resulted from two independent
experiments.
Results
LOH in human gliomas reveals a 130 kb minimally lost 
area uncovering TRIM3
Initial studies had identified an approximately 21 centi-
Morgan region on 11p15.5-pter that showed frequent loss
of heterozygosity in malignant gliomas [35]. This region
has been refined to 7 megabases (Mb) [24], spanning the
region 11p15.4–5 between microsatellite markers (also
called STS) D11S922 and D11S1250 (Fig. 1). Several
genes are contained within this interval that might be
involved in brain development and/or tumor suppres-
sion, including TRIM3 and a cluster of genes encoding the
more distantly related TRIM5,  TRIM6,  TRIM22, and
TRIM34 genes. This area also contains ASCL2 and ASCL3.
Both genes are homologues of the Drosophila genes of the
achaete-scute (ASC) complex that promote cells to develop
a neural fate [36], which therefore may represent addi-
tional candidate brain tumor suppressors encoded by this
region (Fig. 1). We performed loss of heterozygosity anal-
ysis on human brain tumor samples representing 70 pri-
mary gliomas of varying histology and grades including
13 astrocytomas (AS) WHO grades I to III, 10 oligoden-
drogliomas (OG) WHO grade II, and 47 glioblastomas
(GBM). We focused our LOH analysis on the region span-
ning TRIM3 by using 6 microsatellite markers in addition
to the ones that had been used earlier to determine the
minimal area of loss [24].
Among the 70 primary tumor samples tested, 17 out of 70
(24%) showed LOH of at least one marker in this region.
Heterozygous deletions included 12 GBM out of 47 ana-
lysed (25%) consistent with the 11p15.5 deletion fre-
quency previously described in GBM [24]. Further, one
OG grade II out of 10 (10%) showed 11p15.5 allelic loss.BMC Cancer 2009, 9:71 http://www.biomedcentral.com/1471-2407/9/71
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No allelic loss was detected in AS grade I (0/3), while het-
erozygous deletions were observed in 2 AS grade II out of
7 (28%) as well as in 2 AS grade III out of 3 (67%), sug-
gesting a graded escalation of 11p15.5 deletion frequency
with tumor grading in AS (see Table 1 and Fig. 1). Some
of these heterozygous deletions, including OGII 040, ASII
141, and GBM 157, covered the complete region 11p15
(D11S1318, D11S1758, D11S1997, D11S4905,
D11S1331, D11S1250). At the telomeric side, GBM
tumor 167 showed the longest retention proximally
extending to STS marker D11S1997, whereas ASII tumor
031 had the most distal extension of retention to STS
marker D11S4905. Therefore, alignment of our LOH data
with the physical map of the 11p telomeric region delim-
ited a minimal area of loss common to all of these tumors
between markers D11S1997 and D11S4905. This interval
reduced the minimal area of loss from 7 Mb to only 130
kilobases (kb) covering the TRIM3 locus (Fig. 1), and also
pointed to potential breakpoint mutations within the
TRIM3 gene between Exons 3–13.
Genomic dosage alterations of TRIM3 in malignant 
gliomas
In order to refine somatic deletion mapping and to
delimit the minimal area of loss in more detail, we used
single nucleotide polymorphic (SNP) markers located
within the TRIM3 genomic area to further investigate a
selection of tumor samples. For further analysis, we
selected those tumors that were indicative for loss or at
least partial loss of the analysed region at 11p15, namely
GBMs 149, 157, 164, 167, and 211, as well as ASII 031,
ASIII 023, and ASIII 098 (Fig. 2A).
Among the ten SNPs initially selected, six turned out to be
non-informative in all analyzed tumors whereas four
SNPs, namely rs11605881, rs11607224, rs16913748,
rs11605141, displayed loss of heterozygosity or allelic
retention in those tumors selected for further analysis
(Fig. 2). Thus, we observed allelic retention of both paren-
tal alleles of SNPs rs11605881, rs16913748, and
rs11605141 in primary tumors ASII 031 and GBM 211,
respectively. These data displaced the centromeric rim of
the minimally lost area of TRIM3 from STS D11S4905 to
SNP rs11605141 but still targeted the TRIM3 gene (Fig.
2). In addition, in those cases where we observed STS-
based loss of heterozygosity extending on both sides of
the TRIM3 gene (ASIII 098, GBM 157 and GBM 164), the
detected area of LOH was locally interrupted by short sec-
tions with allelic retention at SNPs rs11605881 and
rs11607224. Indeed, tumors ASIII 098 and GBM 164
showed heterozygosity at SNP markers rs11605881 and
rs11607224 located in the TRIM3 promoter and in exon1,
respectively, whereas analysis of markers rs16913748 and
rs11605141 of TRIM3 intron 6 revealed heterozygosity in
GBM 157 (Fig. 2).
Allelic retention within a chromosomal interval display-
ing LOH has been interpreted as a potential site of
homozygous deletion, where retention seems to result
from the amplification of wildtype DNA deriving from
Deletion mapping of chromosomal region 11p15.5 in human  primary gliomas defines a 130 kb-wide area containing TRIM3 Figure 1
Deletion mapping of chromosomal region 11p15.5 in 
human primary gliomas defines a 130 kb-wide area 
containing TRIM3. A. The 11p15.5 chromosomal region 
highlighting TRIM3, the more distantly related TRIM5, TRIM6, 
TRIM22, and TRIM34 genes, as well as ASCL2 and ASCL3; 
arrows indicate transcription orientations. Middle panel: 
somatic deletion of the 11p15.5 region in glioma. Tumor his-
tology, grades and numbers are indicated on the left. Allelic 
retention, allelic loss and non-informative data are repre-
sented by open, closed and grey circles, respectively. Minimal 
and maximal extensions of allelic loss are shown with filled 
and hatched grey areas, respectively. The 11p15 microsatel-
lite markers/sequence tag sites (STS) used are indicated 
(D11S1318, D11S1758, D11S1997, D11S4905, D11S1331, 
D11S1250). Alignment of LOH data delimits a minimal area 
of 130 kb showing LOH common to all 10 tumors between 
markers D11S1997 and D11S4905 which identifies the 
TRIM3 locus. GBMs displaying complete loss of the central 
region were not tested for D11S1318 and D11S1250 (ND). 
B. Informative LOH data with marker D11S4905 comparing 
normal (N) with tumor (T) DNA for brain tumors OGII 040, 
ASIII 098, ASII 141, GBM 157, GBM 164. Abbreviations: 
GBM, Glioblastoma multiforme; AS, astrocytoma; OG, oli-
godendroglioma; RET, retention; LOH, loss of heterozygos-
ity; ND, not determined; NI, non-informative.BMC Cancer 2009, 9:71 http://www.biomedcentral.com/1471-2407/9/71
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non-neoplastic cells present in the tumor biopsy [37].
Thus, SNP-based allelic retention of short sections within
the areas of LOH in primary gliomas ASIII 098, GBM 157,
and GBM 164 indicated potential homozygous deletions
within the TRIM3 gene. In order to investigate this possi-
bility, we targeted four equidistant regions of the TRIM3
gene, including the two areas of possible homozygous
loss in the three primary tumor samples ASIII 098, GBM
157 and GBM 164 by quantitative real-time PCR (Q-
PCR). Analysis of the genetic status of TRIM3 in ASIII 098,
GBM 157, and GBM 164 was assayed on DNA extracted
from both the primary gliomas and peripheral blood
mononuclear cells (PBMCs) derived from the same
patients by Q-PCR of the reference-control gene GAPDH,
as well as for Intron1, Exon 3, Intron 6, and Intron 11 of
TRIM3, respectively (see Methods).
In ASIII 098, tumor genomic dosage in TRIM3 intron 1, at
the site between SNP markers rs11605881 and
rs11607224 indicated DNA levels below haploidy of ΔCt
= -1.98 ± 0.40 (for calculation details, see Methods). These
results signified a homozygous deletion encompassing
TRIM3 intron 1 as already indicated by data of SNP
rs11605881 analysis (Fig. 3). Similarly, Q-PCR analysis of
GBM 157 indicated DNA levels below haploidy from
TRIM3 intron 6 (ΔCt = -1.59 ± 0.20) to intron 11 (ΔCt = -
1.43 ± 0.20), signifying homozygous deletion as already
indicated by SNPs markers rs1693748 and rs1605141
(Fig. 3). In contrast, genomic dosage of primary tumor
GBM 164 indicated continuous diploidy along the TRIM3
gene as exemplified by ΔCt values between -0.30 and
+0.30 of four Q-PCR markers covering intron 1, exon 3,
intron 6 and intron 11 (Fig. 3). Thus, among the 10 pri-
mary human glioma identified with allelic loss at
11p15.5, Q-PCR analysis of ASIII 098 and GBM 157
(20%) indicated homozygous deletions within the TRIM3
gene.
Discussion
In cancer research, conventional strategies of somatic
deletion mapping rely on the detection of frequent sites of
larger DNA alterations. Accordingly, allelic loss of hetero-
zygosity analysis of tumor DNA facilitates the identifica-
tion and localization of a minimally lost area correlating
with candidate tumor suppressor gene loci that might be
involved in the tumorigenic process [38]. In contrast to
these conventional top-down  strategies, we carried out
somatic deletion mapping on human glioma DNA focus-
ing on the TRIM3 locus. We opted for this unorthodox bot-
tom-up  strategy as a result of significant structural
homologies between TRIM3 and the Drosophila  brain
tumor suppressor Brat [19], as well as owing to the fact
that TRIM3 is located on chromosome segment 11p15.5.
Previous analyses demonstrated that chromosome seg-
ment 11p15 contains a region of frequent loss of allelic
heterozygosity in various adult tumors including those of
the brain, lung, breast, ovary, esophagus, stomach, as well
as others [27,35,39-44]. The frequency of LOH in this
region and its apparent correlation with metastatic tumor
spread suggests that this chromosome segment may repre-
sent a hotspot containing one or more tumor suppressor
gene(s).
In the case of brain tumors, a previous LOH study delim-
ited the minimal area of loss to a final 7 Mb-wide genomic
interval spanning several genes with a potential role in
both developing and neoplastic brain tissue [24]. Among
those genes are ASCL2 and ASCL3, mammalian homo-
logues of Drosophila achaete-scute complex [36], as well as
TRIM3, a homologue of Drosophila brain tumor involved in
progenitor cell proliferation control and cancer stem cell
suppression [19], and a cluster of more distantly related
TRIM genes (see Figure 1).
Compared to the earlier study by Schiebe et al. [24], we
analyzed an equivalent number of GBMs (n = 47 vs. n =
50), as well as brain tumors that are distinct in origin, i.e.
OG (n = 10) and AS (n = 13). By focusing on GBM only
(see Table 1), our data revealed similar deletion frequen-
cies (25% vs. 28%) to those previously obtained in GBM
[24]. Interestingly, our deletion analysis revealed
increased frequencies in AS of higher grade, which might
indicate a possible association of 11p15.5 allelic loss with
tumor progression. However, this conclusion needs to be
strengthened by the analysis of a larger number of AS.
Furthermore, as compared to the 7 Mb region previously
described [24], our somatic deletion mapping analysis
delimited a 130 kb-wide minimal area of loss. Thus, our
results rule out ASCL2 and ASCL3 and the more distantly
related TRIM genes as potential glioma tumor suppressors
within the genomic region analyzed. Significantly, the
130 kb-wide minimal area of loss not only identified the
TRIM3  locus, but also indicated potential breakpoint
mutations within the TRIM3 gene.
Table 1: 11p15.5 LOH frequencies among glioma subsets
Histology Number LOH no LOH % LOH
OG II 10 1 9 10
AS I 3 0 3 0
AS II 7 2 5 28
AS III 3 2 1 67
GBM 47 12 35 25
∑ 70 17 53 24
Abbreviations: OG, oligodendroglioma; AS, astrocytoma; GBM, 
Glioblastoma multiforme; I-III, WHO grade; LOH, loss of 
heterozygosity.BMC Cancer 2009, 9:71 http://www.biomedcentral.com/1471-2407/9/71
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SNP-based somatic deletion mapping of chromosomal region 11p15.5 identifies potential breakpoint mutations within the  TRIM3 gene Figure 2
SNP-based somatic deletion mapping of chromosomal region 11p15.5 identifies potential breakpoint muta-
tions within the TRIM3 gene. A. Superimposition of single nucleotide polymorphism (SNP) and sequence tag site (STS)-
based LOH data. (Note that compared to Fig. 1, the map has been inverted to comply with the 5'-3' transcription orientation 
of the TRIM3 gene). STS markers (D11S series) are indicated on the top; tumor histology, grades and numbers are indicated on 
the left. Allelic retention, allelic loss and non-informative data are represented by open, closed and grey circles, respectively. 
Minimal and maximal extension of STS-based areas of allelic loss described in Fig. 1, are shown with filled and hatched grey 
areas, respectively. Areas of local allelic retention defined by SNP analysis within segments of allelic loss defined by STS analysis 
are framed by open rectangles. SNP and STS data, as well as SNP markers (rs series) used are related to a structural map of the 
TRIM3 gene with its coding regions shown in black (bottom). Thus, SNP-based allelic retention of short sections within the 
areas of LOH in primary gliomas ASIII 098, GBM 157, and GBM 164 suggest potential homozygous deletions within the TRIM3 
gene. B. SNP bi-allelism in primary tumors with 11p15.5 allelic loss. Sequence electrophoretograms of genomic DNA 
extracted from primary tumor samples amplified at indicated SNP markers of the TRIM3 gene area; peak color codes: green 
(A), blue (C), black (G), red (T). Abbreviations: GBM, Glioblastoma multiforme; AS, astrocytoma; OG, oligodendroglioma; 
RET, retention; LOH, loss of heterozygosity; NI, non-informative.BMC Cancer 2009, 9:71 http://www.biomedcentral.com/1471-2407/9/71
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We further substantiated our LOH data by single nucle-
otide polymorphism analysis together with quantitative
real-time PCR. Previous studies showed that Q-PCR can
identify micro-deletions providing a reliable approach for
a direct and specific determination of the ploidy status
within defined genetic loci. This approach led to the iden-
tification of homozygous deletions of the p14ARF/
p16INK4a  tumor suppressor locus which is frequently
affected in human gliomas [34]. Significantly, we detected
genomic dosage alterations of TRIM3 in two glioma cases
with LOH at 11p15.5, indicating homozygous deletions
of TRIM3. Our LOH and Q-PCR data therefore suggest
that TRIM3 may act as a tumor suppressor in the human
brain. However, in vitro and mammalian in vivo loss- as
well- as gain-of function analyses are required to deter-
mine the function of TRIM3 in detail. It will be interesting
to see whether TRIM3, similar to its Drosophila homologue
Brain tumor, is involved in the regulation of progenitor
cell proliferation control and brain tumor suppression.
Conclusion
Our analysis identifies loss of allelic heterozygosity at
11p15.5 in 17 cases of primary human glioma and defines
a common 130 kb-wide interval as a minimal area of loss
that covers the TRIM3 locus. In two glioma cases with
LOH, altered genomic dosage of TRIM3  indicates
homozygous deletions. Together, these data suggest
TRIM3 as a 11p15.5 candidate brain tumor suppressor
gene. Further investigation will be needed to elucidate the
biological function of TRIM3 and its precise role in brain
tumor suppression.
Abbreviations
GBM: Glioblastoma multiforme; AS: astrocytoma; OG:
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PCR: quantitative real-time polymerase chain reaction.
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